A new study has used powerful imaging to reveal a subset of Alzheimer's-associated proteins spreading particularly rapidly.

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

This is crucial as the trial’s focus on TREM2 activation, which plays a role in the Amyloid beta pathway associated with Alzheimer’s, could lead to beneficial impacts on brain health beyond amyloid ...

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.